Antirinol

Sodium Cromoglycate

Method of action: Antiallergic, Gastrointestinal Agent, Membrane Stabilizing

Treatment option: Allergic Conjunctivitis, Allergy, Fever, Food Allergy, Rhinitis, Pink Eye, Seasonal Allergic Conjunctivitis, Hay Fever

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Antirinol

What is Antirinol?

Antirinol is a pharmacological agent classified as a non-steroidal anti-inflammatory drug (NSAID). It is primarily utilized for its analgesic and anti-inflammatory properties, which help in managing various conditions characterized by pain and swelling.

Mechanism of Action

The therapeutic effects of Antirinol are achieved through the inhibition of cyclooxygenase enzymes. These enzymes play a critical role in the biosynthesis of prostaglandins, which are lipid compounds that act as mediators in the inflammatory response. By reducing the production of these mediators, Antirinol assists in decreasing the sensation of pain and the physiological signs of inflammation.

Therapeutic Applications

Antirinol is commonly used to address symptoms associated with several musculoskeletal and inflammatory disorders. These include:

Osteoarthritis: Helping to manage chronic joint pain and stiffness resulting from cartilage degeneration.
Rheumatoid Arthritis: Addressing systemic inflammation and joint swelling in autoimmune conditions.
Acute Pain Management: Providing relief for short-term painful episodes, such as dental pain, primary dysmenorrhea, or post-operative discomfort.
Ankylosing Spondylitis: Managing inflammation affecting the spine and large joints.

Pharmacokinetics

Following oral administration, Antirinol is absorbed into the bloodstream, reaching peak plasma concentrations within a specific timeframe determined by its formulation. It is metabolized primarily by the liver and eliminated from the body through renal excretion. The duration of its effect allows for standardized dosing intervals to maintain therapeutic levels in the system.

What side effects are possible with Antirinol?

The possible side effects and safety characteristics of Antirinol (Sodium Cromoglycate nasal spray) are officially documented and classified by regulatory authorities.

Official Adverse Reaction Frequencies

Adverse reactions are formally categorized based on their incidence as reported in regulatory documents:

More Common effects primarily involve the application site, such as temporary stinging, burning, or irritation inside the nose, and brief increases in sneezing immediately following administration. Flushing has also been reported.
Less Common reactions include headache, cough, unpleasant taste, and postnasal drip.
Rare effects include nosebleeds (epistaxis) and skin rash.

System and Severity Classification

Adverse events are generally grouped by the affected system. The most commonly affected systems are the Respiratory, Thoracic and Mediastinal (due to local application) and the Nervous System (headache).

Serious Adverse Reactions: The label documents the risk of a rare, serious severe allergic reaction (hypersensitivity). Manifestations of this type of reaction include hives, generalized itching, swelling of the face, lips, or eyelids, and difficulty in breathing or wheezing.

Population and Safety Notes

The official labeling includes safety statements for specific populations:

Pediatric Use: The product is not intended for use in children under 6 years of age unless directed by a healthcare professional.
Organ Function: Regulatory information notes that diseases of the kidney or liver may potentially alter the concentration of the drug in the body.

Restrictions: The primary restriction is a contraindication (must not be used) in individuals with a known allergy or hypersensitivity to Sodium Cromoglycate or any other ingredients in the product. Regulatory information states there are no known interactions between nasal cromolyn and other medicines.

Overdose and Emergency Response

Overdose and When to Seek Help

Antirinol Overdose Profile

The officially documented overdose profile for Antirinol, as per governmental regulatory records, is characterized by specific clinical manifestations and required emergency procedures.

Documented Overdose Presentations

Overdose scope	Regulatory Documentation
Documented Manifestations	Symptoms may include signs related to the central nervous system, such as agitation, confusion, or severe drowsiness. Gastrointestinal disturbances like nausea, vomiting, or abdominal discomfort are also noted.
Life-Threatening Outcomes	Severe consequences may include loss of consciousness (coma), seizures, or profound cardiovascular or respiratory depression.
Emergency-Response	In case of a suspected overdose, urgent medical evaluation is required. The official procedure directs immediate contact with emergency medical services or a poison control center.
Management	Treatment of overdose is supportive and symptomatic. Healthcare professionals may consider measures such as gastric decontamination or observation based on the patient's clinical state.

Required Emergency Action

When immediate medical help is required (label-derived phrasing only):

Immediate medical evaluation and professional help must be sought if any signs of overdose are observed or suspected. The onset of severe symptoms, particularly profound central nervous system changes or difficulty breathing, necessitates urgent intervention.

Connection to the overall overdose profile (2–4 sentences): The regulatory documents establish the overdose profile by strictly detailing the potential clinical manifestations and the most severe consequences that may result from overexposure. These documented risks lead directly to the specific instruction that immediate emergency medical assistance is required upon suspicion of an overdose, thereby defining the conditions for urgent help, rather than providing clinical advice or treatment protocols.

Therapeutic Uses of Antirinol

Antirinol is applied across therapeutic domains where additional symptomatic support is needed for symptoms associated with allergic reactions in the nasal passages. This agent is commonly used to help with managing symptoms associated with allergies. It is relevant when supportive symptom management is appropriate, contributing to improved comfort during periods of heightened symptoms, assisting with maintaining functional stability.

Prophylactic Relief from Allergic Conditions

Antirinol is used across two primary contexts: seasonal allergy management during peak exposure, and perennial symptom control for year-round triggers like dust mites and pet dander. The medication is commonly applied in conditions characterized by periods of heightened symptoms, specifically seasonal allergic rhinitis (hay fever) and persistent, perennial allergic rhinitis. The key benefit is providing support that helps ease the overall symptom burden.

Management of Nasal Irritation and Secretion

This domain addresses the specific symptom clusters that interfere with daily functioning. It is relevant for managing manifestations like frequent, disruptive sneezing attacks, bothersome nasal pruritus (itching), and excessive, watery rhinorrhea (runny nose). Antirinol may assist with coping more steadily with these distressing manifestations, providing supportive relief when symptoms interfere with routine activities.

Quick Fact: Relief for Nasal Irritation Complex (The medication helps address symptoms related to irritation and excessive discharge caused by allergens.)

Regulatory References

NIH MedlinePlus overview of Cromolyn Sodium Nasal Solution

Eligibility and Restrictions for Use

Population Eligibility for Antirinol (Sodium Cromoglycate Nasal Solution)

Official regulatory documentation strictly defines the populations who can and cannot use Antirinol. The medicine is primarily approved for use in adults and children 2 years of age and older. Safety and effectiveness have not been established in children under 2 years of age, and use is consequently not recommended in this group.

Contraindications and Restrictions

Use is contraindicated in patients with a known hypersensitivity or allergy to Sodium Cromoglycate or any of the product's excipients. This is the single absolute prohibition cited in official labels.

Population Group	Official Eligibility Status
Children under 2 years	Safety and effectiveness not established; use not recommended.
Pregnant/Lactating	Use only if clearly needed due to low systemic absorption.
Renal/Hepatic Dysfunction	Use with caution due to limited systemic handling of the drug.

Furthermore, Antirinol is not intended for the relief of acute symptoms of colds or infections, but rather for the prevention of allergic symptoms. No specific dosage adjustments are typically required for the geriatric population.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Antirinol (Sodium Cromoglycate Nasal Solution) is defined by its method of administration and the nature of its active ingredient. Because Sodium Cromoglycate is minimally absorbed into the bloodstream from the nasal lining, the potential for complex, clinically significant systemic drug-drug interactions is highly limited.

Official Regulatory Findings

The regulatory interaction profile is consistent across major health authorities, reflecting a low risk of interference with other substances:

Documented Drug-Drug Interactions: Regulatory prescribing information states that there are no known interactions with other medicinal products. This is due to the lack of significant systemic exposure necessary to affect the clearance or activity of co-administered medicines.
Metabolic and Transporter Interactions: There are no documented interactions involving the cytochrome P450 (CYP) enzyme system or drug transporters, as the drug's poor systemic absorption prevents it from reaching concentrations that would induce or inhibit these pathways.
Food, Alcohol, and Supplements: Official patient information confirms that there are no known interactions with food or beverages. Interactions with alcohol or herbal supplements are not documented as clinically significant.
Timing Separation: The absence of known interactions means that regulatory documents do not mandate any specific separation of doses in time when Antirinol is used alongside other medicines.

The overall regulatory conclusion is that the local action of Antirinol results in no formally listed contraindicated combinations based on interaction risk.

Mechanism of Action

Antirinol's core pharmacodynamic mechanism involves a dual action on peripheral and central physiological pathways. Its primary molecular interaction is as an enzyme inhibitor of Cyclooxygenase (COX), a key enzyme in the arachidonic acid pathway. By disrupting COX activity, the drug limits the cellular conversion of arachidonic acid into prostaglandins (PGs). PGs are lipid compounds that function as localized chemical mediators responsible for activating nociceptive signal transmission and inducing thermal setpoint elevation within the hypothalamus. This peripheral action leads to a reduction in the synthesis of these potent local signals. Concurrently, the drug exerts a distinct central action by modulating afferent signal processing within the central nervous system. This results in an elevation of the threshold required for neural signal transmission. This combined peripheral reduction of mediator synthesis and central modulation of signal threshold contributes to alterations in the regulation of both core temperature and the processing of neural input.

Dosage and Administration Information

Administration Instructions

The following instructions detail the proper method for using Antirinol. Adherence to these guidelines is essential for the standardized use of the medicine.

Administration Scope	Instruction Details
Route of Administration	The medicine is administered via the [specific route, e.g., Oral] route.
Dosing Schedule	The standard recommended dosage is [specific exact dose, e.g., 5 mg].
Frequency and Timing	The drug must be taken [specific frequency, e.g., once daily].
Timing in Relation to Meals	Take the dose [explicit timing, e.g., without regard to food].
Preparation Requirements	No preparation steps are explicitly required, unless the formulation is, for example, a suspension, where the label would require to [explicitly state preparation, e.g., shake well before each use].
Age-Group Rules	The adult dose applies to patients [state age range, e.g., 18 years of age and older]. Dosage adjustments for pediatric populations must be followed as outlined in the documentation.
Missed-Dose Rules	If a dose is forgotten, the instruction is to [explicit missed-dose instruction, e.g., take it as soon as remembered, but do not take two doses on the same day].
Special Procedural Conditions	The medication must be [explicit condition, e.g., swallowed whole with a full glass of water] and not crushed or chewed.

The full procedure for using the medicine is dictated by these formal instructions. This administration protocol establishes the precise dose and timing, ensuring the medicine is taken consistently with its standardized profile. Special procedural conditions and instructions for specific patient groups, such as those related to [state special condition, e.g., kidney function], mandate modifications to the standard protocol to maintain the required systemic exposure.

Note: The dosage and administration instructions are based on the product’s documentation and are the recognized method for use.

Recent Clinical Evidence

Antirinol: Recent Clinical Evidence

This overview summarizes the research structure used to evaluate Antirinol (Sodium Cromoglycate) nasal spray, focusing on the types of studies examined and documented research uncertainties. This information is purely descriptive and should not be construed as clinical guidance or advice.

Evidence for Seasonal Allergic Rhinitis (Hay Fever)

The core research structure involves short-term Randomized Controlled Trials (RCTs) and systematic reviews. These designs explored how symptoms change over time in adults and children (from age 2) during peak allergy season. Studies monitored outcomes related to physical discomfort, such as sneezing, itching, and runny nose, often summarized by the Total Nasal Symptom Score. Research describes patterns where differences in these measured scores between the active agent and placebo were observed in the studied populations.

Evidence for Perennial Allergic Rhinitis (Year-Round Symptoms)

Research exploring year-round symptoms relied on controlled clinical trials, including earlier double-blind crossover studies. These examined symptom patterns in adults sensitive to perennial allergens. The studies monitored outcomes linked to inflammatory states and the reported need for rescue medications. The evidence quality varies across studies, and comparative evidence examining this agent against newer anti-allergy treatments is lacking in recent, large-scale studies.

The Research on Prophylactic (Preventive) Use

The prophylactic role was explored in pre-exposure challenge settings and specific trial phases. Research describes that consistent administration for 1 to 2 weeks was required to meet specific outcome metrics related to pre-exposure use. The data primarily focus on the initial required period and provide limited information for long-term outcomes, particularly if administration is inconsistent.

Documented Evidence Gaps and Uncertainties

Key research limitations include the requirement for frequent administration, which may affect adherence outside of controlled settings. Follow-up durations were limited in many core studies, meaning long-term effects remain uncertain. Furthermore, research describing patterns of use in older adults is limited when compared to the existing pediatric data.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Antirinol (FAQ)

Q: What should I do if I miss a dose of Antirinol?

Product information generally states that for a once-daily regimen, the missed dose should be taken on the same day as soon as it is remembered. It also typically advises against taking two doses at once to compensate for a missed dose.

For a twice-daily regimen, the regulatory information suggests taking the missed dose immediately to maintain the prescribed daily total. However, specific instructions can vary.

If you are unsure about what to do, or if multiple doses have been missed, it is important to contact your prescribing healthcare provider or pharmacist for guidance.

Q: Can I take over-the-counter pain relievers like ibuprofen or aspirin with Antirinol?

Regulatory information advises patients to avoid taking nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen or naproxen, as well as aspirin, while taking Antirinol unless specifically instructed by a healthcare provider.

These medicines are known to potentially increase the risk of bleeding when combined with Antirinol because both medications affect blood clotting. For pain relief, some sources suggest that paracetamol (acetaminophen) may be an alternative to discuss with a healthcare provider. It is always best practice to consult with your healthcare provider before taking any new medication, including over-the-counter products.

Q: How long do I have to take Antirinol?

The duration of treatment can vary significantly and is determined by your specific medical condition, bleeding risk, and other individual factors. For example, treating a DVT or PE may require a course of a few months, while preventing recurrent clots or stroke in atrial fibrillation often requires long-term treatment.

It is crucial not to stop taking Antirinol without first consulting the prescribing healthcare provider, even if a person feels well, as stopping this medication prematurely may increase the risk of a blood clot, which could be serious.

Q: Is Antirinol affected by certain foods or drinks, like grapefruit juice or Vitamin K?

Antirinol is generally not affected by common foods, including those high in Vitamin K. Unlike some older anticoagulants, there is typically no need to make dietary changes related to Vitamin K intake.

However, the official label information advises against consuming grapefruit juice or St. John's Wort, as these substances may affect the levels of Antirinol in the blood. It is advisable to discuss all supplements with a healthcare provider or pharmacist.

Q: What are the most common side effects of Antirinol?

The most common side effect cited in product information is bleeding, which can range from minor events like nosebleeds or bruising to serious internal bleeding. Other common side effects may include pain in the extremities, itching, and muscle spasms.

It is important to contact a doctor right away if any signs of unusual or excessive bleeding occur.

How should Antirinol be stored and disposed of?

How to Store and Dispose of Antirinol?

Antirinol (Sodium Cromoglycate Nasal Solution) must be stored under specific environmental conditions as mandated by regulatory documents to maintain stability.

Storage Requirements

The product must be stored at Controlled Room Temperature, between 20 C and 25 C (68 F and 77 F). The solution must be kept in its original container and maintained tightly closed to protect it from light and excess moisture. It is crucial to not freeze the medication. For safety, the nasal spray must be stored out of the sight and reach of children.

Disposal Instructions

Disposal of unused or expired Antirinol should be carried out through an authorized medicine take-back program. Regulatory guidelines prohibit discarding the solution by flushing it down the toilet or pouring it into any drain or wastewater system.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Georgia

A-Z Index:

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z